Reporting of Adverse Events and Unanticipated Problems
|
|
- Trevor Ward
- 7 years ago
- Views:
Transcription
1 Reporting of Adverse Events and Unanticipated Problems Policy date: 12/2011 Purpose The purpose of this policy is to ensure that the review, reporting and analysis of adverse events and unanticipated problems associated with Cancer protocols occur in a timely, meaningful way so that human subjects can be protected from avoidable harms. Policy This policy will outline the procedure to ensure prompt reporting to the Board, appropriate institutional officials, sponsor, coordinating center and the appropriate regulatory agency heads of adverse events and unanticipated problems involving risks to participants or others. This policy also includes procedures for the Principal Investigator (PI) and IRB with regard to reporting and review of adverse events and unanticipated problems. Due to the number and frequency of events that occur in cancer research, it is the intention of the IRB to focus its review on the reporting of serious adverse events and/or unanticipated problems to enhance the protections of research participants. This will ensure that the IRB, along with reports, monitoring, and oversight by a Data Safety Monitoring Board/Data Monitoring Committee, will provide a meaningful review to ongoing cancer research. Definitions Adverse event: any unfavorable or unintended event, physical or psychological, associated with a research study, which causes harm or injury to a research participant as a result of the participant s involvement in a research study. The event can include abnormal laboratory findings, symptoms, or disease associated with the research study. The event does not necessarily have to have a causal relationship with the research, any risk associated with the research, the research intervention, or the research assessments. Adverse events may be the result of the interventions and interactions used in the research; the collection of identifiable private information in the research; an underlying disease, disorder, or condition of the subject; and/or other circumstances unrelated to the research or any underlying disease, disorder, or condition of the subject. In general, adverse events that are at least partially the result of (a) or (b) would be considered related to the research, whereas adverse events solely related to (c) or (d) would be considered unrelated to the research. Page 1 of 11
2 Expected adverse event: an event previously known or anticipated to result from participation in the research study or any underlying disease, disorder, or condition of the subject. The event is usually listed in the Investigator Brochure, consent form or research protocol. Unexpected adverse event: an adverse event not previously known or anticipated to result from the research study or any underlying disease, disorder, or condition of the subject. External adverse events: adverse events experienced by subjects enrolled in multicenter clinical trials at sites other than the site(s) over which the Board has jurisdiction. Internal adverse events: adverse events experienced by subjects enrolled at the site(s) under the IRB s jurisdiction for either multicenter or single-center research projects. In the case of an internal adverse event the PI typically becomes aware of the adverse event directly from the subject, another collaborating local investigator, or the subject s healthcare provider. Studies approved by the IRB but conducted outside the United States are considered internal for the purposes of adverse event reporting. Please also refer to definitions of types of research. Unanticipated problems: those events that (1) are not expected given the nature of the research procedures and the subject population being studied; (2) related or possibly related to the participation in the research project; and (3) suggest that the research places subjects or others at a greater risk of harm or discomfort related to the research than was previously known or recognized. Unanticipated problems may or may not be related to adverse events or protocol deviations. Note: In written guidance by the United States Department of Health and Human Services (HHS) Office for Human Research Protections (OHRP), OHRP clarifies that only a small subset of adverse events that occur in human subjects participating in research meet the criteria for an unanticipated problem involving risks to subjects or others. Significance of an adverse event: is used to describe the patient/event outcome or action criteria associated with events that pose a threat to a patient s life or functioning (i.e., moderate, severe or life threatening). Based on the National Cancer Institute Guidelines for the Cancer Therapy Evaluation Program, severity can be defined by the following grades of events: Grade 1 are mild adverse events. (e.g., minor event requiring no specific medical intervention; asymptomatic laboratory findings only; marginal clinical relevance) Grade 2 are moderate adverse events (e.g., minimal intervention; local intervention; non-invasive intervention; transfusion; elective interventional radiological procedure; therapeutic endoscopy or operation). Page 2 of 11
3 Grade 3 are severe and undesirable adverse events (e.g., significant symptoms requiring hospitalization or invasive intervention; transfusion; elective interventional radiological procedure; therapeutic endoscopy or operation). Grade 4 are life threatening or disabling adverse events (e.g., complicated by acute, life-threatening metabolic or cardiovascular complications such as circulatory failure, hemorrhage, sepsis; life threatening physiologic consequences; need for intensive care or emergent invasive procedure; emergent interventional radiological procedure, therapeutic endoscopy or operation). Grade 5 is a fatal adverse event resulting in death. Serious adverse event: any adverse experience occurring at any dose that results in any of the following outcomes: death, a life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood disease or disorders, or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse. (Defined by United States Department of Department of Health and Human Service Food and Drug Administration, or FDA, regulations at 21 CFR (b), (a), and (a).) Interventional studies: these studies include research designed to evaluate the safety, effectiveness, or usefulness of therapies (e.g., drugs, vaccines, supplements, diet, exercise, surgical interventions, or medical devices), diagnostic procedures (e.g., scans, biopsies, or endoscopies) or preventive measures (e.g., vaccines or diet). Interventional studies include procedures, both invasive and non-invasive. The procedures include those that are done solely for research purposes and represent no apparent benefit to the participant (e.g., bone marrow aspiration or bronchoscopy in normal, healthy volunteers). Non-interventional and observational studies: these studies include research that does not involve any intervention, alteration in standard clinical care or use in participants of any invasive or non-invasive procedures. Studies limited to the recording of data on individuals receiving standard medical care, the use of existing specimens or data, or the retrospective review of health information and outcomes are, for the purposes of this policy, considered observational studies. Specific types of research that may be classified as observational include database registries, chart reviews, longitudinal outcomes data collection, certain types of survey and questionnaire research, certain types of epidemiological and behavioral studies, and analysis of patient samples. Page 3 of 11
4 Procedure Reporting requirements The primary responsibility for the evaluation of reportability to the IRB lies with the PI of the research project. This includes the documentation, investigation, and follow-up of these events. The mechanism and required time-frame of reporting to the IRB varies depending on the type of research study, significance, attribution, and expectedness of the event, whether it occurred internally or externally, and if it is an adverse event that is also an unanticipated problem. Additional details of the reporting requirements are included in the tables, below. At the time of continued review for an IRB-approved protocol, the PI will submit a summary of all reportable serious adverse events, including those determined to be unanticipated problems, to the IRB. The summary should include a simple and brief statement as to whether there have been any unanticipated problems and whether adverse events have occurred at the expected frequency and level of severity as documented in the research protocol, the informed consent document, and/or any investigator brochure. If new risks to the participants are identified because of an adverse event(s) that results in substantive changes to the research project, the requests for modifications to the research must be submitted to the IRB with an amendment to research request. Examples of substantive changes that might need to be considered in response to adverse events include: modification of inclusion or exclusion criteria to mitigate the newly identified risks; implementation of additional monitoring procedures for the safety of subjects; termination of enrollment of new subjects; modification of informed consent documents to include a description of newly recognized risks; and incorporation of changes to the study to address serious adverse events that are expected in some subjects, but are determined to be occurring at a significantly higher frequency or severity than expected. NOTE: The IRB does not require the PI to report adverse events that occur to subjects enrolled in observational or non-interventional studies unless the event is related to study participation, causes a change in study design, increases risk to participants or others and/or represents an unanticipated problem. Please note that reporting an event to the IRB does not relieve the PI of the requirement or obligation to report the event to other agencies such as the FDA, Data Safety Monitoring Board/Data Monitoring Committee, or the study sponsors. For multicenter research, the PI should consult with the study sponsor or coordinating center regarding any changes to the protocol and/or informed consent documents. The PI also must ensure that the adverse event is reported to the central or independent monitoring entity in accordance with the monitoring plan described in the IRB approved protocol. Page 4 of 11
5 Unanticipated problems: All events determined to be an unanticipated problem must be promptly reported to the IRB for review. The Board may take action appropriate for the circumstances to protect the safety, welfare and rights of research subjects. The IRB will report internal adverse events determined to be unanticipated problems to the supporting HHS agency head (or designee) and OHRP. These reports will include the same type of information provided to the IRB by the PI, along with a summary of the actions taken by the IRB and institutional officials in response to the unanticipated problem(s). If the PI determines that the adverse event is an anticipated problem, the PI needs to ensure that the internal adverse event is reported to a central or independent monitoring entity in accordance with the monitoring plan described in the IRB approved protocol. If the monitoring entity subsequently determines, in contrast to the PI s determination, that the serious adverse event does represent an unanticipated problem, the monitoring entity should communicate this determination to the PI, who then should report the unanticipated problem to the IRB. When a central monitoring entity determines that a particular adverse event or series of adverse events represents an unanticipated problem, a report of the adverse event(s) must be submitted to the PI and the IRB. If possible, reports of external adverse events submitted to the IRB should present the adverse event in the context of the entire multicenter study. In addition, the local PI should consult with the study sponsor or coordinating center regarding any changes to the protocol and/or informed consent documents independently proposed by the local PI. These central monitoring reports of external adverse events that are determined to be unanticipated problems should include: 1) A clear explanation of why the adverse event or series of adverse events has been determined to be an unanticipated problem; and 2) A description of proposed actions to be taken by the investigators and/or IRB in response to the unanticipated problem (e.g., suspension of new subject enrollment, modification of the research protocol, and/or modification of the informed consent process). Reports with no modifications to the study: As determined by the review of the IRB chairperson (or designee), reportable events may be handled as follows: 1) Filed in the IRB records without further review by the IRB and included as part of a report of actions taken on behalf of the board or, Page 5 of 11
6 2) Clarified through the following process: If the central monitoring entity or the PI did not propose any modifications to the protocol or informed consent process/document, but the IRB Chair (or designee) believes that modifications or additional information are needed in response to the reportable adverse event(s), the IRB chairperson (or designee) requests in writing that the PI discuss the proposed modifications with the study sponsor or coordinating center and submit a response or necessary modifications for review by the IRB or, 3) Referred, at the discretion of the IRB Chair (or designee) to the rest of the IRB members for review and further action, as appropriate, at a convened meeting. Under HHS regulations at 45 CFR (a), the IRB has authority to require submission of more detailed contextual information by the PI, the sponsor, the study coordinating center, or Data Safety Monitoring Board/Data Monitoring Committee about any adverse event occurring in a research protocol as a condition of the continuation of the IRB s approval of the research. Reports with modifications to the study: As determined by the review of the IRB chairperson (or designee), reportable events may be handled as follows: 1) The IRB Chair (or designee) requests in writing that the PI discuss the proposed additional modifications with the study sponsor or coordinating center and submit a response or the necessary additional modifications for review by the IRB. 2) If all proposed modifications represent minor changes, the IRB Chair (or designee) may review and, if appropriate, approve the modifications under an expedited review procedure (45 CFR (b)). All IRB members are informed of the expedited approval (45 CFR (c)), and the report of the external adverse event will be filed in the IRB records. 3) If any of the proposed modifications represent more than a minor change, or if the IRB Chair (or designee) determines for any reason that he or she should not approve the proposed modifications under an expedited review procedure, the proposed modifications will be forwarded to the other IRB members for review at a convened meeting. Adverse events on a different protocol: If a PI is notified or made aware of adverse event(s), including fatal adverse events, that occurred in a study related (e.g. same study agent, device, subject population and/or procedure) to, but not the same as UH Cancer IRB-approved protocol, the adverse event(s) should only be reported to the UH Cancer IRB if the adverse event results in a change in the UH Cancer protocol, consent form, or the perceived risk/benefit ratio. If changes are required, the PI should follow the procedures outlined in the above-labeled Page 6 of 11
7 section, Reports with modifications to the study. If changes are not required, the reports should be kept on file by the PI. Investigator time requirement for reporting adverse events and/or unanticipated problems to the IRB: NOTE: Time requirements to report events to other agencies such as the FDA, Data Safety Monitoring Board/Data Monitoring Committee, or the study sponsors, may be different than those required by the IRB. The PI is responsible for being aware of and reporting events in accordance with all applicable timelines. PIs shall submit to the IRB site-specific reports of reportable adverse events and/or unanticipated problems involving risks to subjects or others according to the time frames listed below (days are determined by date of discovery or notice to the PI). External Adverse Events Significance of Study Related Not Study Related Adverse Event (Possible/Probable/Definite) (Unrelated/Unlikely) Expected Unexpected Expected Unexpected Fatal Events (Grade 5) 5 working days* Life-Threatening or disabling (Grade 4) Page 7 of 11
8 Severe and undesirable (Grade 3) Moderate and Mild (Grades 1 & 2) Unanticipated Problem that is a Reportable Event 5 working days *All study related, unexpected deaths should be carefully assessed against the definition of an unanticipated problem. Internal Adverse Events Significance of Study Related Not Study Related Adverse Event (Possible/Probable/Definite) (Unrelated/Unlikely) Expected Unexpected Expected Unexpected Fatal Events (Grade 5) 5 working days 5 working days* 10 working days Life-Threatening or disabling (Grade 4) 10 working days Page 8 of 11
9 Severe and undesirable (Grade 3) 10 working days Moderate and Mild (Grades 1 & 2) Unanticipated Problem that is a Reportable Event 5 working days and reportable to HHS agency head and OHRP *All study related, unexpected deaths should be carefully assessed against the definition of unanticipated problem. IRB Review and Reporting Procedures: The IRB s review of an adverse event and/or unanticipated problem will include analysis of the following information: 1) The description of known or foreseeable adverse events and risks in the IRBapproved research protocol, any applicable investigator brochure, the current IRBapproved informed consent document, and other relevant sources of information, such as scientific literature, product labeling, and package inserts; 2) Any underlying diseases or conditions of the subject(s) experiencing the adverse event; 3) A careful assessment of whether the adverse event is related or possibly related to subject s participation in the research study; and Page 9 of 11
10 4) An analysis of whether the risk versus potential benefit of the research is altered as a result of the adverse event and a determination of whether the adverse event warrants consideration of substantive changes in the research protocol or informed consent process/document. At the time of continued review for an IRB-approved protocol, the IRB will request a summary of all reportable adverse events, including those determined to be unanticipated problems, to be included in s submitted to the IRB by investigators. The summary should include a simple and brief statement as to whether there have been any unanticipated problems and whether adverse events have occurred at the expected frequency and level of severity as documented in the research protocol, the informed consent document, and/or any investigator brochure. Notification of IRB Actions The IRB shall notify the PI in writing of its actions in approving, accepting, disapproving or requiring changes to (in order to approve or accept) the reportable adverse event(s) report(s) for an IRB approved protocol. A disapproval notice shall include the basis for the disapproval and provide an opportunity for the investigator to address the Board in person or in writing regarding its action. All such written correspondence from the UH Cancer IRB will be signed by the UH Cancer IRB Chairperson or his designee who will be named by written correspondence. Reporting to the Institution and Government Agencies The administrative office of the UH Cancer IRB shall notify and cooperate with the General Counsel and the appropriate federal agencies in accordance with the Reporting to Regulatory Agencies, Department Heads and Institutional Officials policy. Regulatory Citations: 21 CFR CFR CFR CFR CFR 46 Page 10 of 11
11 Related Policies and Procedures: Non-compliance with Human Subject Regulations [Version ] Reporting to Federal Agencies, Department Heads and Institutional Officials [Version ] Guidance: NIH Guidelines on Reporting Adverse Events to Institutional Review Boards, June 11, 1999 OHRP Guidance January 15, Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events FDA Guidance January Adverse Event Reporting s Improving Human Subject Protection FDA Good Clinical Practice Program National Cancer Institute, Cancer Therapy Evaluation Program - CTEP, NCI Guidelines: Adverse Event Reporting Requirements, Effective January 1, 2005 Page 11 of 11
Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events
Office for Human Research Protections (OHRP) Department of Health and Human Services (HHS) Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events
More informationIOWA STATE UNIVERSITY Institutional Review Board. Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others
IOWA STATE UNIVERSITY Institutional Review Board Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others Introduction This policy details the Institutional Review Board
More informationST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB
More informationLaurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute
Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute Understand the protocol completely Recognize institutional polices
More informationAdverse Events in Clinical Trials: Definitions and Documentation
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators Adverse Events in Clinical Trials: Definitions
More informationGuidance on IRB Continuing Review of Research
NOTE: THIS GUIDANCE SUPERSEDES OHRP S JANUARY 15, 2007 GUIDANCE ENTITILED GUIDANCE ON CONTINUING REVIEW. CLICK HERE FOR THE JANUARY 15, 2007 GUIDANCE. Office for Human Research Protections Department of
More informationInvestigator responsibilities for research conducted under the authority of the UTHSCSA Institutional Review Board (IRB)
March 1, 2006 M E M O R A N D U M F O R R E C O R D TO: FROM: SUBJECT: Deans Department Chairs Principal Investigators Brian Herman, Ph.D. Vice President for Research Investigator responsibilities for
More informationEffective Date: October 2015
University of Maryland Greenebaum Cancer Center UMGCC Standard Operating Procedure Title: Data & Safety Monitoring Plan Effective Date: October 2015 Procedure No: DSM001 University of Maryland Greenebaum
More informationGENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):
Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS
More informationPrincipal Investigator and Sub Investigator Responsibilities
Principal Investigator and Sub Investigator Responsibilities I. Purpose To define the roles and responsibilities of Principal Investigators conducting research at GRU. II. Definition The term Principal
More information12.0 Investigator Responsibilities
v. 5.13.13 12.0 Investigator Responsibilities 12.1 Policy Investigators are ultimately responsible for the conduct of research. Research must be conducted according to the signed Investigator statement,
More informationStandard Operating Procedures
Standard Operating Procedures Ffff H a r v a r d L o n g w o o d M e d i c a l A r e a Office of Human Research Administration 90 Smith St. Suite 335 Boston, MA 02120 617-432-3071/ 617-432-2157 www.hsph.harvard.edu/ohra
More informationPHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE
PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE PART A: TRIAL INFORMATION A1. Title of Clinical Trial (as stated in proposed Protocol) Protocol No.
More informationGuidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues
Office for Human Research Protections (OHRP) Department of Health and Human Services (HHS) Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues This guidance represents
More informationSAN DIEGO COMMUNITY COLLEGE DISTRICT INSTITUTIONAL REVIEW BOARD (IRB) INVESTIGATOR GUIDELINES FOR RESEARCH USING HUMAN SUBJECTS
BACKGROUND SAN DIEGO COMMUNITY COLLEGE DISTRICT INSTITUTIONAL REVIEW BOARD (IRB) INVESTIGATOR GUIDELINES FOR RESEARCH USING HUMAN SUBJECTS The first priority of the SDCCD Institutional Review Board (IRB)
More informationGuidance for IRBs, Clinical Investigators, and Sponsors
Guidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval U.S. Department of Health and Human Services Food and Drug Administration Center for
More informationGuidance for IRBs, Clinical Investigators, and Sponsors. Considerations When Transferring Clinical Investigation Oversight to Another IRB
Guidance for IRBs, Clinical Investigators, and Sponsors Considerations When Transferring Clinical Investigation Oversight to Another IRB U.S. Department of Health and Human Services Food and Drug Administration
More informationSeries 1 Case Studies Adverse Events that Represent Unanticipated Problems: Reporting Required
Welcome! This document contains three (3) series of Case Study examples that will demonstrate all four OHSU reporting categories (#1 4) as well as examples of events that are considered not reportable.
More informationPrincipal Investigator Responsibilities for Education and Social/Behavioral Researchers
Principal Investigator Responsibilities for Education and Social/Behavioral Researchers Introduction The purpose of this module is to provide a basic understanding of the responsibilities of the principal
More informationMedicine Safety Glossary
The following definitions are provided as a resource to supplement the information provided in the Medicine Safety Education section of the Pfizer.com Web site; they are not intended as a comprehensive
More informationData Management in Clinical Trials
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 19, 2013 Diane St. Germain, RN, MS Nurse Consultant Division of Cancer Prevention National Cancer
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/876333/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions Draft finalised by the Agency in collaboration with Member States 7 February 2012 Definitions
More informationINVESTIGATOR HANDBOOK
INVESTIGATOR HANDBOOK Liberty IRB, Inc. 1450 S. Woodland Blvd., Suite 300A Deland, Florida 32720 Phone (386) 279-4318 Fax: (386)868-4563 Website: www.libertyirb.com Business hours: Monday Friday, 8:00am
More informationData Management & Case Report Form Development in Clinical Trials. Introduction to the Principles and Practice of Clinical Research.
Data Management & Case Report Form Development in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 3, 2015 Marge Good, RN, MPH, OCN Nurse Consultant Division of
More informationClinical Trials and Safety Surveillance of Drugs in Development
Clinical Trials and Safety Surveillance of Drugs in Development Hoda Eid, M.Sc., Ph.D. Manager, ADR Unit Office of Clinical Trials Therapeutic Products Directorate hoda_eid@hc-sc.gc.ca Overview Clinical
More informationThis policy applies to research administrators, investigators, research staff, Human Investigation Committee (HIC) members and HIC staff.
REVIEW BY AN EXTERNAL INSTITUTIONAL REVIEW BOARD 233 1 of 5 PURPOSE The purpose of this policy is to establish a procedure for requesting authorization for an approved, external (non-beaumont) institutional
More informationPage 191 TITLE 21 FOOD AND DRUGS 355 1
Page 191 TITLE 21 FOOD AND DRUGS 355 1 APPEALS TAKEN PRIOR TO OCTOBER 10, 1962 Section 104(d)(3) of Pub. L. 87 781 made amendments to subsec. (h) of this section inapplicable to any appeal taken prior
More informationNova Southeastern University Institutional Review Board Policies and Procedures
Page 1 of 14 Purpose: To establish policy with respect to the emergency use of unapproved drugs and biologics. Definitions: 1. IRB approval means the determination of the IRB that the research has been
More informationUniversity of California Davis. Investigator Manual. Revised March 10, 2016
University of California Davis Investigator Manual Revised March 10, 2016 HRP-103 03/10/2016 2 of 41 Table of Contents Scope... 3 What is the purpose of this manual?... 3 What is Human Research?... 3 What
More informationTopics for today. Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports. Post-marketing Submissions
Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports Martha A. Feldman, RAC Drug & Device Development Co., Inc. Topics for today Post-approval requirements for
More informationStudy Protocol Template
Study Protocol Template (Chart Reviews) Instructions: This protocol template is a tool to facilitate the development of a study protocol specifically designed for the investigator initiated studies. It
More informationGuidance for Clinical Investigators, Sponsors, and IRBs
Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection U.S. Department of Health and Human Services Office of the Commissioner (OC) Center
More informationAdverse Events: Documenting, Recording, and Reporting
Adverse Events: Documenting, Recording, and Reporting Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Introduction Monitoring of adverse
More informationUniversity of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol
University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of
More informationICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Step 5
European Medicines Agency June 1995 CPMP/ICH/377/95 ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting Step 5 NOTE FOR GUIDANCE ON CLINICAL SAFETY DATA MANAGEMENT:
More informationReliance Agreement for Institutions Utilizing Stony Brook University s Institutional Review Board(s)
Name of Organization Providing IRB Review: Stony Brook University ( SBU IRB ) Name of Institution Relying on the SBU IRB ( Institution ): Latest AAHRPP Accreditation Date (if applicable) OHRP Federal Wide
More informationGUIDELINES ON MEDICAL DEVICES
EUROPEAN COMMISSION DG Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Health technology and Cosmetics MEDDEV 2.7/3 revision 3 May 2015 GUIDELINES ON
More informationIRB Submissions and Human Subjects Research Compliance. Georgia Health Sciences University
IRB Submissions and Human Subjects Research Compliance Offi f H R hp t ti Office of Human Research Protection Georgia Health Sciences University Objectives Identify the steps required to submit a protocol
More informationLEBANESE MINISTRY OF HEALTH DIRECTIVE
LEBANESE MINISTRY OF HEALTH DIRECTIVE LAYING DOWN DETAILED GUIDELINES FOR SPONSORS OF CLINICAL TRIALS March 2012 Field of Application General Considerations Trial s submission Validity of the F-MRI opinion
More informationHollie Goddard Sr. IRB Coordinator McKesson Specialty Health
Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health We are responsible for acquiring, analyzing, and protecting medical information vital to providing quality patient care HIM professionals ensure
More informationPOST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING E2D
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS
More informationVertex Investigator-Initiated Studies Program Overview
Vertex Investigator-Initiated Studies Program Overview Our Goal To support independent, investigator-initiated research designed to advance scientific knowledge of disease states, patient populations,
More informationThis policy applies to all clinical research conducted at Beaumont Health System.
CLINICAL RESEARCH QUALITY AND PROCESS IMPROVEMENT PROGRAM 113 1 of 6 PURPOSE Prior The purpose of this policy is to provide an overview of the Clinical Research Quality and Process Improvement Program
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities
This Guidance Document is to ensure that investigators and research personnel recognize their responsibilities associated with the conduct of human subject research by outlining their responsibilities,
More informationAttachment B HIPAA-P03 Instructions for Completing IU s Authorization for Research Purposes
Attachment B HIPAA-P03 Instructions for Completing IU s Authorization for Research Purposes The HIPAA Privacy Rule generally prohibits health care providers from using or releasing protected health information
More informationSubject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
More informationHealth Products and Food Branch. www.hc-sc.gc.ca
Health Products and Food Branch 1 HEALTH CANADA PART C DIVISION 5 - DRUGS FOR CLINICAL TRIALS INVOLVING HUMAN SUBJECTS Part C - Division 5 2 Part A: Part B: Part C: Part D: Part E: Part G: Part J: Administration
More informationNova Southeastern University Institutional Review Board Policies and Procedures
Nova Southeastern University Institutional Review Board Policies and Procedures Monitoring of Approved Research, Approval Duration, and Continuing Review Effective 03/08/2007; Revised 10/14/2010; 8/29/2011;
More informationIf you are signing for a minor child, you refers to your child throughout the consent document.
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY Adult Patient or Parent, for Minor Patient INSTITUTE: National Cancer Institute PRINCIPAL INVESTIGATOR: Raffit Hassan, M.D. STUDY TITLE: Tissue Procurement
More informationThe Importance of Following the PROTOCOL in Clinical Trials
The Importance of Following the PROTOCOL in Clinical Trials Presentation Objectives: Upon completion of this presentation, participants will be able to: Describe the following terms: Protocol, Protocol
More informationGuidance for Industry
Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center
More informationCDISC Data Standards Can Facilitate Composition of Adverse Event Narratives
CDISC Data Standards Can Facilitate Composition of Adverse Event Narratives Anisa Scott, Ph.D. and Richard C. Zink, Ph.D. JMP Life Sciences SAS Institute, Inc. anisa.scott@jmp.com Copyright 2010 SAS Institute
More informationTracy Walker, RN, BSN, CCRP Research Nurse OHSU Knight Cancer Institute. 503-346-1183 walkertr@ohsu.edu
Tracy Walker, RN, BSN, CCRP Research Nurse OHSU Knight Cancer Institute 503-346-1183 walkertr@ohsu.edu Exercise Questions to Keep in Mind Is there an adverse event? What is the severity? What is the relationship
More informationCONDUCTING GLOBAL CLINICAL RESEARCH TRIALS:
CONDUCTING GLOBAL CLINICAL RESEARCH TRIALS: COMPARING AND CONTRASTING FDA MEDICAL DEVICE REGULATIONS FOR CLINICAL INVESTIGATORS WITH ISO 14155:2011 Introduction Today s clinical research landscape for
More informationApplication Guide. 2015 Global Awards in Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) Research
Application Guide 2015 Global Awards in Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) Research A Competitive Grants Program Supported by Pfizer www.aspireresearch.org Table of Contents THE ASPIRE
More informationReport from NHRPAC. The Common Rule for the protection of human subjects of research (45 CFR 46) includes a definition of minimal risk:
The content of this document does not represent the official views or policies of the Office for Human Research Protections (OHRP) nor of the Department of Health and Human Services (HHS). The content
More informationClinical Trials: Questions and Answers
Clinical Trials: Questions and Answers Key Points Clinical trials are research studies that test how well new medical approaches work in people (see Question 1). Every clinical trial has a protocol, which
More informationYale Cancer Center Data and Safety Monitoring Committee Charter
Yale Cancer Center Data and Safety Monitoring Committee Charter Purpose/Mission The purpose of the Yale Cancer Center (YCC) Data and Safety Monitoring Committee (DSMC) is to provide ongoing data and safety
More informationInvestigational Drugs: Investigational Drugs and Biologics
: I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place
More informationExpanded Access Programs. Richard Klein Office of Special Health issues Food and Drug Administration
Expanded Access Programs Richard Klein Office of Special Health issues Food and Drug Administration Expanded Access Programs (EAPs) What is expanded access? History Legislative background General principles
More informationInformation Sheet Guidance For IRBs, Clinical Investigators, and Sponsors
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Frequently Asked Questions About Medical Devices Additional copies are available from: Office of Good Clinical Practice Office
More informationRole of the Investigational Drug Services (IDS) in the Management of Investigational Drugs
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs Charlesworth Rae, BS, PharmD, JD Investigational Drug Pharmacist July 2012 1 Outline of Presentation I. Introduction
More informationHAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES
Pursuant to section 453-1.5, Hawaii Revised Statutes, the Board of Medical Examiners ("Board") has established guidelines for physicians with respect to the care and treatment of patients with severe acute
More informationSTANDARD OPERATING POLICY AND PROCEDURE
STANDARD OPERATING POLICY AND PROCEDURE SUBJECT: Biospecimen Request and Release Policy Number: 500.0 Policy Date: 1/16/2009 Amendment Date: N/A Revision Date: 5-3-2010 I. INTRODUCTION AND PURPOSE The
More informationSpecial Considerations for Pediatric Trials
Special Considerations for Pediatric Trials Clinical research with minors poses several significantly different issues than research conducted on adults. Therefore, researchers must address a number of
More informationGuidance Medication Guides Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)
Guidance s Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationUNIVERSITY PHYSICIANS OF BROOKLYN, INC. POLICY AND PROCEDURE. No: Supersedes Date: Distribution: Issued by:
UNIVERSITY PHYSICIANS OF BROOKLYN, INC. POLICY AND PROCEDURE Subject: ALCOHOL & SUBSTANCE ABUSE INFORMATION Page 1 of 10 No: Prepared by: Shoshana Milstein Original Issue Date: NEW Reviewed by: HIPAA Policy
More informationTIMEFRAME STANDARDS FOR UTILIZATION MANAGEMENT (UM) INITIAL DECISIONS
ADMINISTRATIVE POLICY TIMEFRAME STANDARDS FOR UTILIZATION MANAGEMENT (UM) INITIAL DECISIONS Policy Number: ADMINISTRATIVE 088.15 T0 Effective Date: November 1, 2015 Table of Contents APPLICABLE LINES OF
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies Appendix I of the Guidelines for the Clinical Translation of Stem Cells www.isscr.org 2008, International Society for Stem Cell Research 2 Introduction We have all
More informationMedical Billing Human Research Studies Seminar Notes
Audits If a department learns that an external audit is going to be initiated, the Billing Compliance Department and Research Administration should be notified when the scope of the audit involves billing
More informationHuman Research Protection Program University of California, San Diego ISSUES ON DNA AND INFORMED CONSENT
Human Research Protection Program University of California, San Diego ISSUES ON DNA AND INFORMED CONSENT Regulatory changes will occur for investigators studying human DNA The recent acceleration and widening
More informationPMAs, 510(k)s, and Advanced IDE Topics
PMAs, 510(k)s, and Advanced IDE Topics Kenneth J. Cavanaugh Jr., Ph.D. Scientific Reviewer Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health kenneth.cavanaugh@fda.hhs.gov
More informationWHEN I WANT TO: I NEED TO SUBMIT: {for CIRB studies, see the specific FAQ}
IRB forms and materials to be submitted WHEN I WANT TO: I NEED TO SUBMIT: {for CIRB studies, see the specific FAQ} 1 2 Request a determination as to whether AHC is the appropriate IRB of record (i.e. is
More information483.25(i) Nutrition (F325) Surveyor Training: Interpretive Guidance Investigative Protocol
483.25(i) Nutrition (F325) Surveyor Training: 1 With regard to the revised guidance F325 Nutrition, there have been significant changes. Specifically, F325 and F326 were merged. However, the regulatory
More informationClinical Trials Reporting Program (CTRP) and Clinicaltrials.gov (CT.gov) Helpful tips and guidance
Clinical Trials Reporting Program (CTRP) and Clinicaltrials.gov (CT.gov) Helpful tips and guidance Objectives NCI s Clinical Trials Reporting Program (CTRP) Overview CTRP What is it? CTRP is an NCI mandated
More informationGuidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationPolicy of the National Institute of Nursing Research for Data and Safety Monitoring of Extramural Clinical Trials
Policy of the National Institute of Nursing Research for Data and Safety Monitoring of Extramural Clinical Trials Purpose and Scope This policy sets forth the National Institute of Nursing Research (NINR)
More informationStandard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s. Lisa Austin, Research Manager
Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s Author: Lisa Austin, Research Manager Purpose and Objective: To identify and standardise
More informationUNIFORM HEALTH CARRIER EXTERNAL REVIEW MODEL ACT
Model Regulation Service April 2010 UNIFORM HEALTH CARRIER EXTERNAL REVIEW MODEL ACT Table of Contents Section 1. Title Section 2. Purpose and Intent Section 3. Definitions Section 4. Applicability and
More informationOPERATING PROCEDURES
OPERATING PROCEDURES CATEGORY: RESEARCH AFFAIRS CODE: H-27A APPROVED: 8/17/2010 SUBJECT: PROCEDURES FOR CONDUCT OF CONVENED IMPLEMENTED: 11/2010 REPLACES: PAGE: 1 of 6 Please note: Definitions are found
More informationRE: Human Research Subject Protections Under Federalwide Assurance FWA-7 145
Office of the Secretary DEPARTMENT OF HEALTH & HUMAN SERVICES Office of Public Health and Science Donald E. Wilson, M.D., M.A. Dean, School of Medicine University of Maryland Baltimore Professional Schools
More informationCancer Clinical Trials: In-Depth Information
Cancer Clinical Trials: In-Depth Information The Drug Development and Approval Process 1. Early research and preclinical testing 2. IND application filed with FDA 3. Clinical trials (phases 1, 2, and 3)
More informationDHHS/NIH/OD/OIR/OHSRP 1/2/2015
DHHS/NIH/OD/OIR/OHSRP 1/2/2015 The audience for this course is Principal Investigators (PIs), investigators and Research Coordinators (RCs) serving on the study team of human clinical studies and trials.
More informationPerspectives on Patient Recruitment
Webcast Perspectives on Patient Recruitment Sponsors: Presenters Moderator: Christiane Truelove Editor in Chief, R&D Directions Chris.Truelove@ubm.com Speakers: Dr. Bradley Vince, D.O., President and Medical
More informationGuidance for Industry and Investigators
Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationQuality Monitoring Checklist
Quality Monitoring Checklist Instructions: For each task below, the Quality Monitor indicates in the appropriate column if the Monitor accomplished the task by using the following codes Yes No N/A = Monitor
More informationGuidance for Industry Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions
Guidance for Industry Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions U.S. Department of Health and Human Services Food and Drug Administration Center for
More informationINFORMED CONSENT FOR SLEEVE GASTRECTOMY
INFORMED CONSENT FOR SLEEVE GASTRECTOMY This informed-consent document has been prepared to help inform you about your Sleeve Gastrectomy including the risks and benefits, as well as alternative treatments.
More informationGuidance on the Genetic Information Nondiscrimination Act: Implications for Investigators and Institutional Review Boards
Office for Human Research Protections (OHRP) Department of Health and Human Services (HHS) Guidance on the Genetic Information Nondiscrimination Act: Implications for Investigators and Institutional Review
More informationNo. 706. Page 1 of 5. Issue Date 4/21/2014
Subject: ROUTINE MONITORING VISITS Standard Operating Procedure Prepared By: Beaumont Research Coordinating Center, Research Institute PURPOSE Prior Issue Date 8/15/2011 No. 706 Issue Date 4/21/2014 Page
More informationFACT SHEET (Available at http://prsinfo.clinicaltrials.gov/) Registration at ClinicalTrials.gov: As required by Public Law 110-85, Title VIII
10/27/09 NOTE: Section 2, Timing of Registration at ClinicalTrials.gov, was revised on 10/23/09. This document supersedes the Fact Sheet issued on 11/09/07. Note that the new text is highlighted below.
More informationStudy Start-Up SS-204.01. STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV)
Study Start-Up SS-204.01 STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV) Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval: Frederick M. Schnell,
More informationCLINICAL RESEARCH ROLES CLINICAL RESEARCH ROLESCLINICAL RESEARCH ROLES
CLINICAL RESEARCH ROLESCLINICAL RESEARCH ROLES 1. Clinical Study Team Principal Investigator Co Principal Investigator (Co PI) Research Coordinator Study Monitor Data manage Sponsor Post Doctoral Scholar
More informationGOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE
ICH E6 GCP: Consolidated Guideline: Investigator 1/7 Institutional Review Board Services ICH HARMONIZED TRIPARTITE GUIDELINE E6: GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE 4. INVESTIGATOR 4.1 Investigator's
More informationEthics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient
More information2 Applicability: Effective Date: 1/15/2010 Revised: 8/13/2010, 9/10/10, 5/9/14
2 Applicability: Effective Date: 1/15/2010 Revised: 8/13/2010, 9/10/10, 5/9/14 NDSU research may involve the collaboration or assistance of other research institutions, schools, hospitals, clinics, private
More informationProtecting Personal Health Information in Research: Understanding the HIPAA Privacy Rule
AA Privacy RuleP DEPARTMENT OF HE ALTH & HUMAN SERVICES USA Protecting Personal Health Information in Research: Understanding the HIPAA Privacy Rule NIH Publication Number 03-5388 The HI Protecting Personal
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationTitle: Department: Approved by:
Title: Department: Emergency Use of an Investigational Drug or Biological Product, or Unapproved Medical Device Human Research Affairs Policy Type: Partners System-wide Partners System-wide Template Partners
More informationMiami University: Human Subjects Research General Research Application Guidance
Miami University: Human Subjects Research General Research Application Guidance Use the accompanying Word template for completing the research description. You must provide sufficient information regarding
More information